Vera Therapeutics (NASDAQ:VERA – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They currently have a $107.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 167.37% from the company’s previous close.
Separately, JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of “Buy” and a consensus price target of $51.75.
Get Our Latest Report on Vera Therapeutics
Vera Therapeutics Price Performance
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, research analysts forecast that Vera Therapeutics will post -2.59 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Marshall Fordyce sold 15,625 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 21.70% of the company’s stock.
Institutional Trading of Vera Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Crestline Management LP increased its stake in Vera Therapeutics by 32.4% in the 4th quarter. Crestline Management LP now owns 60,069 shares of the company’s stock worth $924,000 after purchasing an additional 14,689 shares during the period. Rafferty Asset Management LLC raised its position in Vera Therapeutics by 25.2% during the 4th quarter. Rafferty Asset Management LLC now owns 170,758 shares of the company’s stock valued at $2,626,000 after purchasing an additional 34,381 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Vera Therapeutics in the 4th quarter worth approximately $17,087,000. Pale Fire Capital SE bought a new stake in shares of Vera Therapeutics in the 4th quarter worth approximately $252,000. Finally, Kynam Capital Management LP increased its stake in shares of Vera Therapeutics by 23.5% during the fourth quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock valued at $56,142,000 after buying an additional 694,286 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- 3 Small Caps With Big Return Potential
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Using the MarketBeat Stock Split Calculator
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.